Similar articles

• Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

  Zhu LL, Feng ZJ, Zhou Q. Zhu LL, et al. Clin Interv Aging. 2015 Mar 26;10:621-2. doi: 10.2147/CIA.S82435. eCollection 2015. Clin Interv Aging. 2015. PMID: 25848238 Free PMC article. No abstract available.
• Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications.

  Zhang LT, Lee SW, Park K, Chung WS, Kim SW, Hyun JS, Moon DG, Yang SK, Ryu JK, Yang DY, Moon KH, Min KS, Park JK. Zhang LT, et al. Clin Interv Aging. 2015 Jan 17;10:277-86. doi: 10.2147/CIA.S74102. eCollection 2015. Clin Interv Aging. 2015. PMID: 25653511 Free PMC article. Clinical Trial.
• [LUTS in BPH patients : Comparison of silodosin versus tamsulosin, naftopidil, alfuzosin and placebo for the treatment of lower urinary tract symptoms].

  Praus F, Miernik A. Praus F, et al. Urologe A. 2019 Jul;58(7):795-798. doi: 10.1007/s00120-019-0955-9. Urologe A. 2019. PMID: 31143977 Review. German. No abstract available.
• Re: Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement.

  Kaplan SA. Kaplan SA. J Urol. 2015 Mar;193(3):948. doi: 10.1016/j.juro.2014.12.036. Epub 2014 Dec 18. J Urol. 2015. PMID: 25765413 No abstract available.
• Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015.

  Schauer I, Madersbacher S. Schauer I, et al. Curr Opin Urol. 2015 Jan;25(1):6-11. doi: 10.1097/MOU.0000000000000120. Curr Opin Urol. 2015. PMID: 25393269 Review.